Literature DB >> 15564818

Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology.

Laurence L Greenhill1, Benedetto Vitiello, Prudence Fisher, Jerome Levine, Mark Davies, Howard Abikoff, Allan K Chrisman, Shirley Chuang, Robert L Findling, John March, Lawrence Scahill, John Walkup, Mark A Riddle.   

Abstract

OBJECTIVE: To improve the gathering of adverse events (AEs) in pediatric psychopharmacology by examining the value and acceptability of increasingly detailed elicitation methods.
METHOD: Trained clinicians administered the Safety Monitoring Uniform Report Form (SMURF) to 59 parents and outpatients (mean age +/- SD = 11.9 +/- 3.2 years) in treatment, with 36% on stimulants, 29% on selective serotonin reuptake inhibitor drugs, 10% on both, and 25% on other drug combinations. The SMURF included a brief general inquiry, a drug-specific inquiry, and a comprehensive body system review (BSR).
RESULTS: SMURF administration took 24.6 +/- 13.9 minutes (median, 21). The BSR took 15.5 +/- 8.1 minutes (median, 14) longer (p < .0001) than the general inquiry (4.3 +/- 5.4 minutes) and the drug-specific inquiry (4.2 +/- 2.9 minutes). The general inquiry elicited 48 AEs, the drug-specific inquiry elicited 16 additional AEs, and the BSR 129 additional AEs. Of all the clinically relevant AEs elicited by the SMURF (n = 36), 19 (53%) were elicited by the BSR. The BSR length and detail were acceptable to parents but not to clinicians.
CONCLUSIONS: The BSR elicited additional clinically significant AEs that had been missed with less detailed methods. Parents, but not clinicians, rated satisfaction and acceptability of the BSR as good.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15564818     DOI: 10.1097/01.chi.0000142668.29191.13

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  36 in total

1.  Child/Adolescent anxiety multimodal study: evaluating safety.

Authors:  Moira A Rynn; John T Walkup; Scott N Compton; Dara J Sakolsky; Joel T Sherrill; Sa Shen; Philip C Kendall; James McCracken; Anne Marie Albano; John Piacentini; Mark A Riddle; Courtney Keeton; Bruce Waslick; Allan Chrisman; Satish Iyengar; John S March; Boris Birmaher
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2014-12-31       Impact factor: 8.829

2.  Advances in the treatment of pediatric obsessive-compulsive d-cycloserine with exposure and response prevention.

Authors:  Joseph F McGuire; Adam B Lewin; Daniel A Geller; Ashley Brown; Kesley Ramsey; Jane Mutch; Andrew Mittelman; Jamie Micco; Cary Jordan; Sabine Wilhelm; Tanya K Murphy; Brent J Small; Eric A Storch
Journal:  Neuropsychiatry (London)       Date:  2012-08

3.  Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial.

Authors:  Christoph U Correll; Linmarie Sikich; Gloria Reeves; Jacqueline Johnson; Courtney Keeton; Marina Spanos; Sandeep Kapoor; Kristin Bussell; Leslie Miller; Tara Chandrasekhar; Eva M Sheridan; Sara Pirmohamed; Shauna P Reinblatt; Cheryl Alderman; Abigail Scheer; Irmgard Borner; Terrence C Bethea; Sarah Edwards; Robert M Hamer; Mark A Riddle
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

4.  The Food and Drug Administration's deliberations on antidepressant use in pediatric patients.

Authors:  Laurel K Leslie; Thomas B Newman; P Joan Chesney; James M Perrin
Journal:  Pediatrics       Date:  2005-07       Impact factor: 7.124

5.  Side effects from use of one or more psychiatric medications in a population-based sample of children and adolescents.

Authors:  Robert J Hilt; Monica Chaudhari; Janice F Bell; Christine Wolf; Kent Koprowicz; Bryan H King
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-02-07       Impact factor: 2.576

6.  Lithium for the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled Discontinuation Study.

Authors:  Robert L Findling; Nora K McNamara; Mani Pavuluri; Jean A Frazier; Moira Rynn; Russell Scheffer; Vivian Kafantaris; Adelaide Robb; Melissa DelBello; Robert A Kowatch; Brieana M Rowles; Jacqui Lingler; Jian Zhao; Traci Clemons; Karen Martz; Ravinder Anand; Perdita Taylor-Zapata
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2018-11-26       Impact factor: 8.829

7.  A Double-Blind Placebo-Controlled Trial of Omega-3 Fatty Acids as a Monotherapy for Adolescent Depression.

Authors:  Vilma Gabbay; Rachel D Freed; Carmen M Alonso; Stefanie Senger; Jill Stadterman; Beth A Davison; Rachel G Klein
Journal:  J Clin Psychiatry       Date:  2018-06-26       Impact factor: 4.384

Review 8.  A Review of the Safety, Efficacy and Mechanisms of Delivery of Nasal Oxytocin in Children: Therapeutic Potential for Autism and Prader-Willi Syndrome, and Recommendations for Future Research.

Authors:  Marilena M DeMayo; Yun Ju C Song; Ian B Hickie; Adam J Guastella
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

9.  Improving reporting of adverse drug reactions: Systematic review.

Authors:  Mariam Molokhia; Shivani Tanna; Derek Bell
Journal:  Clin Epidemiol       Date:  2009-08-09       Impact factor: 4.790

10.  Psychotropic medication monitoring checklists: use and utility for children in residential care.

Authors:  Ajit Ninan; Shannon L Stewart; Laura Theall; Gillian King; Ross Evans; Philip Baiden; Al Brown
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2014-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.